Leveraging the Immune System for Therapeutic Benefit in Non-Small Cell Lung Cancer: Scientific Insights, Clinical Applications and Future Directions


AACR19/Lung

Module 1: Emergence of Immune Checkpoint Inhibition as a Therapeutic Consideration for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Track 1: Efficacy of consolidation durvalumab after chemoradiation therapy for Stage III NSCLC on the PACIFIC trial; synergy between immune checkpoint inhibitors and chemoradiation therapy
Track 2: Benefit with durvalumab after chemoradiation therapy; role of the abscopal effect of radiation therapy
Track 3: Utility of durvalumab for patients with locally advanced NSCLC and targetable mutations or low PD-L1 expression
Track 4: Role of durvalumab as consolidation therapy for patients who undergo surgical resection for locally advanced NSCLC
Track 5: Risk of disease progression for patients who receive chemoradiation therapy followed by durvalumab consolidation
Track 6: Absolute reduction in the risk of disease progression with durvalumab; optimal duration of durvalumab consolidation therapy

Module 2: Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-1/PD-L1 Antibodies for Locally Advanced and Metastatic Disease

Track 7: Frequency of and reasons for discontinuing therapy with immune checkpoint inhibitors
Track 8: Incidence, severity and time to onset of pneumonitis on the PACIFIC trial
Track 9: Use of anti-PD-1/PD-L1 antibodies for patients with preexisting autoimmune disease and for transplant recipients
Track 10: Effect of the chemotherapy backbone on toxicities with immune checkpoint inhibitors
Track 11: Spectrum of toxicities with anti-PD-1/PD-L1 antibodies

Module 3: Current Application of Immune Checkpoint Inhibitors in the Treatment of Metastatic NSCLC; Role for Patients with Actionable Tumor Mutations

Track 12: Selection of first-line therapy for patients with metastatic NSCLC and no targetable mutation
Track 13: Selection of first-line therapy for patients with metastatic NSCLC and EGFR mutations
Track 14: Duration of therapy with anti-PD-1/PD-L1 antibodies for patients with metastatic NSCLC
Track 15: Role of immune checkpoint inhibitors in combination with targeted therapy
Track 16: Efficacy of anti-PD-1/PD-L1 antibodies in patients with BRAF mutations
Track 17: PD-L1 expression and response to immune checkpoint inhibitors

Module 4: Future Directions for Clinical and Translational Research

Track 18: Activity of immune checkpoint inhibitors in patients with NSCLC in the neoadjuvant setting
Track 19: Correlation between tumor mutation burden and response to immune checkpoint inhibitors; efficacy of checkpoint inhibitors alone versus in combination
Track 20: Modulation of tumor response to immunotherapy by the gut microbiome

 
FACULTY
 
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
 
Vali A Papadimitrakopoulou, MD
Jay and Lori Eisenberg Distinguished Professor
Section Chief
Thoracic Medical Oncology
Professor of Medicine
Department of Thoracic/HN Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Naiyer Rizvi, MD
Price Family Professor of
Medicine at CUMC
Columbia University Medical Center
Director
Thoracic Oncology Program
Co-Director
Immunotherapy in the
Department of Medicine
Research Director
Price Family Comprehensive Center
for Chest Care at NewYork-Presbyterian Hospital
New York, New York
 
David R Spigel, MD
Chief Scientific Officer
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida